공시 • Jan 05

+ 4 more updates

SomaLogic, Inc. (NasdaqGM:SLGC) completed the acquisition of Standard BioTools Inc. (NasdaqGS:LAB) from Viking Global Opportunities Illiquid Investments Sub-Master LP and Viking Global Opportunities Drawdown (Aggregator) LP, managed by Viking Global Investors LP and others.

SomaLogic, Inc. (NasdaqGM:SLGC) entered into a definitive agreement to acquire to acquire Standard BioTools Inc. (NasdaqGS:LAB) from Viking Global Opportunities Illiquid Investments Sub-Master LP and Viking Global Opportunities Drawdown (Aggregator) LP, managed by Viking Global Investors LP and others for approximately $570 million in a reverse merger transaction on October 4, 2023. Under the terms of the agreement, SomaLogic shareholders will receive 1.11 shares of Standard BioTools common stock for each share of SomaLogic common stock owned. Upon the close of the transaction, Standard BioTools shareholders will own approximately 43% of the combined company, and SomaLogic shareholders will own approximately 57% of the combined company on a fully diluted basis. Upon close, the combined company’s Board will consist of seven directors, three of whom will be designated by Standard BioTools: Michael Egholm, Fenel Eloi and Frank Witney, and three of whom will be designated by SomaLogic: Tom Carey, who will serve as Chairman, Troy Cox and Kathy Hibbs. Eli Casdin will also continue to serve on the combined company’s Board. Upon close, Michael Egholm will serve as Chief Executive Officer, Jeff Black will serve as Chief Financial Officer and Alex Kim will serve as Chief Operating Officer. Adam Taich will serve as the combined company’s Chief Strategy Officer, and Shane Bowen, Chief Research and Development Officer of SomaLogic, will serve as Chief Technology Officer. The combined company will operate under the Standard BioTools name with facilities in California, Colorado, Massachusetts, Canada and Singapore. Upon termination of the Merger Agreement by Standard BioTools under specified circumstances, Standard BioTools may be required to pay SomaLogic a termination fee of $19,123,214. Upon termination of the Merger Agreement by SomaLogic under specified circumstances, SomaLogic may be required to pay Standard BioTools a termination fee of $17,176,173. Transaction is subject to regulatory approval; approval by both companies’ stockholders; expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976; authorization for listing on The Nasdaq Stock Market of the shares of Standard BioTools Common Stock (including the shares to be issued in the Merger), subject to official notice of issuance; effectiveness of the Registration Statement and satisfaction of other customary closing conditions. Transaction has been unanimously approved by the board of SomaLogic and Standard BioTools. Stockholders representing approximately 16% of Standard BioTools common stock and approximately 1% of SomaLogic common stock, including the directors and executive officers of each company and affiliated investment funds, have entered into voting agreements in support of the transaction. The HSR Waiting Period expired at 11:59 p.m., Eastern Time, on November 20, 2023. The transaction is expected to close in the first quarter of 2024. The transaction is expected to generate $80 million in annual cost synergies by 2026. As of January 4, 2024, SomaLogic and Standard BioTools stockholders voted to approve the transaction. The merger is expected to close on January 5, 2024, subject to satisfaction of certain customary closing conditions. Centerview Partners LLC is serving as financial advisor and fairness opinion provider to Standard BioTools, and Matthew J. Gardella and Matthew W. Tikonoff of Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. serving as its legal counsels. Perella Weinberg Partners LP and Cowen and Company, LLC are serving as financial advisors to SomaLogic, with Perella Weinberg Partners LP as lead and fairness opinion provider. Julia Forbess, Stefano Quintini, Matt Cantor, Laura McIntyre, Antonia Sequeira, Dan McCoy, Tom Ensign, Jennifer Yoo, William Skinner, Mark Jansen, Ana Razmazma, Ethan A. Skerry and David Michaels of Fenwick & West LLP is serving as legal advisors to SomaLogic. Computershare Trust Company, National Association is a transfer agent to Standard BioTools Inc. Blair Thetford of Skadden, Arps, Slate, Meagher & Flom LLP represented Perella Weinberg Partners LP as financial advisor to SomaLogic, Inc. Alliance Advisors, LLC acted as proxy solicitor to Standard BioTools. Standard BioTools estimates that it will pay Alliance Advisors a fee of approximately $25,000, plus reimbursement of reasonable expenses. Morrow Sodali LLC acted as proxy solicitor to SomaLogic and will receive a services fee of $20,000 plus the reimbursement of customary disbursements. Continental Stock Transfer & Trust Company acted as transfer agent to SomaLogic. PWP will receive an aggregate fee of $6 million, $1.5 million of which became payable in connection with the delivery of PWP’s opinion and $4.5 million (the “Transaction Fee”) of which is contingent upon the consummation of the Merger. Perella Weinberg Partners LP and Fenwick & West LLP acted as due diligence providers to SomaLogic. SomaLogic, Inc. (NasdaqGM:SLGC) completed the acquisition of Standard BioTools Inc. (NasdaqGS:LAB) from Viking Global Opportunities Illiquid Investments Sub-Master LP and Viking Global Opportunities Drawdown (Aggregator) LP, managed by Viking Global Investors LP and others on January 5, 2024. Michael Egholm, Jeff Black and Alex Kim will continue to serve as Chief Executive Officer, Chief Financial Officer and Chief Operating Officer of Standard BioTools, respectively. Adam Taich, SomaLogic’s Interim Chief Executive Officer, has been appointed as Chief Strategy Officer of Standard BioTools and Shane Bowen, SomaLogic’s Chief Research and Development Officer, has been appointed as Chief Technology Officer of Standard BioTools. Tom Carey, Troy Cox and Kathy Hibbs have joined the Standard BioTools Board of Directors and Tom Carey has been appointed as Chairman of the Board. Carlos Paya, Laura Clague and Martin Madaus – who served on the Standard BioTools Board until the closing of the merger, have resigned from the Standard BioTools Board.

공시 • Oct 06

SomaLogic, Inc. (NasdaqGM:SLGC) entered into a definitive agreement to acquire to acquire Standard BioTools Inc. (NasdaqGS:LAB) from Viking Global Opportunities Illiquid Investments Sub-Master LP and Viking Global Opportunities Drawdown (Aggregator) LP, managed by Viking Global Investors LP and others for approximately $570 million in a reverse merger transaction.

Life Sciences 이익 성장	17.6%
매출 성장률	16.4%
향후 자기자본이익률	n/a
애널리스트 커버리지	Low
마지막 업데이트	04 Jan 2024

날짜	매출	이익	자유현금흐름	영업현금흐름	평균 애널리스트 수
12/31/2026	140	-69	N/A	-81	2
12/31/2025	118	-84	N/A	-87	2
12/31/2024	99	-100	N/A	-91	4
12/31/2023	84	-111	N/A	-113	4
9/30/2023	82	-130	-122	-117	N/A
6/30/2023	101	-141	-139	-134	N/A
3/31/2023	95	-139	-144	-138	N/A
12/31/2022	98	-109	-106	-101	N/A
9/30/2022	102	-83	-96	-92	N/A
6/30/2022	80	-92	-75	-70	N/A
3/31/2022	86	-82	-46	-42	N/A
12/31/2021	82	-88	-44	-40	N/A
9/30/2021	87	-73	-27	-23	N/A
6/30/2021	81	-39	-13	-11	N/A
3/31/2021	68	-45	-22	-21	N/A
12/31/2020	56	-53	-29	-28	N/A
12/31/2019	32	-57	-51	-51	N/A

데이터	최종 업데이트 (UTC 시간)
기업 분석	2024/01/09 09:59
종가	2024/01/05 00:00
수익	2023/09/30
연간 수익	2022/12/31

패키지	데이터	기간	미국 소스 예시 ^*
기업 재무제표	10년	손익계산서 현금흐름표 대차대조표	SEC 양식 10-K SEC 양식 10-Q
분석가 컨센서스 추정치	+3년	재무 예측 분석가 목표주가	분석가 리서치 보고서 Blue Matrix
시장 가격	30년	주가 배당, 분할 및 기타 조치	ICE 시장 데이터 SEC 양식 S-1
지분 구조	10년	주요 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
경영진	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발	10년	회사 공시	SEC 양식 8-K

분석가	기관
Kyle Mikson	Canaccord Genuity
Brandon Couillard	Jefferies LLC
Daniel Brennan	TD Cowen

This company has been acquired

Standard BioTools 향후 성장

Future 기준 점검 1/6

핵심 정보

최근 향후 성장 업데이트

Somalogic, Inc. Provides Revenue Guidance for Fourth Quarter and Full Year 2023

Consensus estimates of losses per share improve by 10%

SomaLogic, Inc. Raises Revenue Guidance for the Full Year 2023

SomaLogic, Inc. (NASDAQ:SLGC) Just Reported, And Analysts Assigned A US$3.93 Price Target

Price target decreased by 21% to US$3.93

SomaLogic, Inc. Reiterates Revenue Guidance for the Full Year 2023

Recent updates

Somalogic, Inc. Provides Revenue Guidance for Fourth Quarter and Full Year 2023

Nasdaq Files an Application on Form 25 with Commission to Remove the Shares of SomaLogic Common Stock and Warrants from Listing on the Nasdaq Capital Market

SomaLogic, Inc. (NasdaqGM:SLGC) completed the acquisition of Standard BioTools Inc. (NasdaqGS:LAB) from Viking Global Opportunities Illiquid Investments Sub-Master LP and Viking Global Opportunities Drawdown (Aggregator) LP, managed by Viking Global Investors LP and others.

Boston Millennia Partners Intends to Vote Against Proposed Merger with Standard BioTools Inc.

Madryn Asset Management Releases Evidence that SomaLogic Ran an Incomplete Review of Alternatives

Madryn Asset Management, LP Issues Presentation to SomaLogic Shareholders

Why Investors Shouldn't Be Surprised By SomaLogic, Inc.'s (NASDAQ:SLGC) P/S

SomaLogic, Inc. Announces Demise of Eliot M. Lurier, Interim Chief Financial Officer

Consensus estimates of losses per share improve by 10%

SomaLogic, Inc. Raises Revenue Guidance for the Full Year 2023

SomaLogic, Inc. (NASDAQ:SLGC) Just Reported, And Analysts Assigned A US$3.93 Price Target

Price target decreased by 21% to US$3.93

Somalogic Announces New Somascan® 11K Platform

SomaLogic, Inc. to Report Q3, 2023 Results on Nov 08, 2023

New minor risk - Share price stability

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

SomaLogic, Inc. to Report Q2, 2023 Results on Aug 14, 2023

Somalogic, Inc. Announces Chief Financial Officer Changes

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

SomaLogic, Inc. Reiterates Revenue Guidance for the Full Year 2023

SomaLogic, Inc. (NASDAQ:SLGC) Stocks Shoot Up 33% But Its P/S Still Looks Reasonable

Less than half of directors are independent

Downgrade: Here's How Analysts See SomaLogic, Inc. (NASDAQ:SLGC) Performing In The Near Term

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

SomaLogic, Inc. Provides Revenue Guidance for Full Year 2022

Price target decreased to US$6.50

Consensus forecasts updated

High number of new and inexperienced directors

SomaLogic appoints former Foundation Medicine chief as executive chair

Consensus forecasts updated

Price target decreased to US$7.75

Price target decreased to US$11.50

SomaLogic acquires Palamedrix to develop next-generation SomaScan Assay

We're Hopeful That SomaLogic (NASDAQ:SLGC) Will Use Its Cash Wisely

Price target decreased to US$14.50

High number of new and inexperienced directors

Independent Director exercised options to buy US$275k worth of stock.

SomaLogic Inc: A Biopharmaceutical Company With An Excellent Upside

Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind

Now 24% undervalued after recent price drop

Calculating The Intrinsic Value Of SomaLogic, Inc. (NASDAQ:SLGC)

High number of new and inexperienced directors

We Think SomaLogic (NASDAQ:SLGC) Can Easily Afford To Drive Business Growth

Third quarter 2021 earnings released: US$0.55 loss per share

SomaLogic: The Highest Number Of Proteins Analyzable In A Single Blood Sample In Proteomics

Director recently bought US$160k worth of stock

No independent directors

이익 및 매출 성장 예측

애널리스트 향후 성장 전망

주당순이익 성장 예측

향후 자기자본이익률

성장 기업 찾아보기

기업 분석 및 재무 데이터 상태

데이터 소스

분석 모델 및 스노우플레이크

산업 및 섹터 지표

분석가 소스